LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective immediately.
Roberts brings over 30 years of experience in scientific innovation and product development, launching hundreds of products while building global R&D teams. He joins the Company most recently from Pharmavite, a consumer-packaged goods Company which manufactures the Nature Made line of vitamins, minerals, and supplements, where he served as Chief Technology & Quality Officer. Previously, Roberts drove growth across the food, nutrition, and agriculture sectors at The Nature’s Bounty Company, Abbott Nutrition, and Nestlé. He has been on the ChromaDex Scientific Advisory Board since November 2016.
“Having spent two years on the ChromaDex Scientific Advisory Board, Matthew is already quite familiar with the outstanding scientific and operations capabilities at the Company,” says ChromaDex CEO Rob Fried. “He also brings a wealth of knowledge and experience in consumer product development, international regulatory approvals and general business strategy. We are proud to have him join our Company.”
“I’m very excited to be joining ChromaDex. Having served on the Scientific Advisory Board, I’ve seen first-hand the Company’s commitment to apply breakthrough science and product quality to healthy aging,” says Roberts. “As Chief Scientific Officer, I’m looking forward to building on that foundation to further develop the science, technical excellence, and our talented team.”
Roberts holds a PhD in Comparative and Environmental Toxicology from Cornell University and an Executive MBA from Washington University in St. Louis. He serves on the Nutrition Capital Network innovation screening committee and has served on the Corporate Advisory Board of the Cold Spring Harbor Laboratory, which advances biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology.
About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the capabilities of Mr. Roberts in consumer product development, international regulatory approvals and general business strategy and his ability to help further develop the Company’s science and technical excellence. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. ChromaDex provided research materials and a portion of the grant funding as a collaborator for the study.
ChromaDex Media Contact:
Alex Worsham, Director of Strategic Partnerships
949-648-3775
alexw@chromadex.com
ChromaDex Investor Relations Contact:
Brianna Gerber, Sr. Director of FP&A and Investor Relations
949-344-3782
briannag@chromadex.com